---

Market Overview

---

The global IVD raw materials market had a value of USD 24.34 billion in 2021, and it is projected to reach USD 34.25 billion by 2027, growing at a CAGR of 5.86% throughout the forecast period.

The increasing prevalence of chronic conditions and expanding patient populations are driving the demand for diagnostics and laboratory tests. The market share of antigen and antibody-based tests witnessed significant growth during the COVID-19 pandemic, resulting in its major contribution to the market. It is expected to experience the highest incremental growth of USD 3.92 billion and an absolute growth rate of 44.41% during the forecast period.

Europe stands as a mature market for in-vitro diagnostics, with highly automated large laboratory instruments compared to point-of-care testing devices. Automation has improved the speed and ease of device use, aided by a thoroughly trained and adaptable workforce. Furthermore, the global IVD raw materials market is anticipated to witness an incremental growth of USD 9.91 billion and an absolute growth rate of 40.73% by 2027.

The growing trends of point-of-care diagnostics and personalized medicine are significant contributors to the expansion of the IVD raw materials market. Investments in the development and commercial launch of IVD instruments and rapid test kits for diagnosing various infectious diseases, as well as their applications in the research segment, will further propel the market in developed countries.

In 2021, pharma & biotech companies held the largest market share of 62.19% in the global IVD raw materials market. However, diagnostic laboratories are expected to witness the highest absolute growth rate of 43.37% during the forecast period.

Vendors offer a wide range of high-quality enzymes that are well-suited for manufacturing diagnostic kits and reagents. Manufacturers are also exploring new enzyme sources from a vast pool of enzymes, optimizing and transforming them into the most suitable enzyme molecules.

---

Market Segmentation

---

The market is segmented based on various factors, including product, technology, end-user, and geography.

Segmentation Analysis by Product
Antibody & Antigen
Enzymes
Proteins
Biological Buffers
Others

Segmentation Analysis by Technology
Clinical Chemistry
Immunochemistry
Molecular Diagnostics
Others

Segmentation Analysis by End-User
Pharma & Biotech Companies
Diagnostic Laboratories
Others

Segmentation by Geography
North America – US, Canada
Europe – Germany, France, UK, Italy, Spain
APAC – China, Japan, India, South Korea, Australia
Latin America – Brazil, Mexico, Argentina
Middle East & Africa – South Africa, Saudi Arabia, Turkey

The IVD raw materials market offers a wide range of products applicable to clinical chemistry methods, enabling the development of rapid tests that provide immediate test results. It is projected that the global IVD raw materials market focused on clinical chemistry will reach a value of USD 12.14 billion by 2027.

Recently, there has been a notable expansion in the presence of private laboratories, particularly in developing countries. This expansion has significantly stimulated the growth of the market. Additionally, the prevalence of epidemic and pandemic conditions worldwide has led to an increased demand for standalone reference laboratories. As a result, the global IVD raw materials market focused on diagnostic laboratories is expected to grow at a compound annual growth rate (CAGR) of over 6% between 2022 and 2027.

In terms of regional dominance, Europe took the lead in the global IVD raw materials market in 2021, surpassing other regions. Europe is recognized as a mature market that boasts well-developed diagnostic infrastructure in most countries. The presence of advanced healthcare infrastructure in European countries has driven the demand for advanced molecular diagnostics. Furthermore, the latest trend in the European market is the adoption of point-of-care diagnostics. It is anticipated that the Europe IVD raw materials market will reach a value of USD 11.80 billion by 2027.

---

Competitive Landscape

---

Prominent manufacturers of IVD raw materials are placing their focus on proprietary processing techniques that meet the specific requirements of the IVD industry. They aim to provide off-the-shelf IVD raw materials that adhere to their own specifications. These manufacturers consistently allocate resources towards research and development projects aligned with market trends and the demand for general health management. Additionally, key players actively pursue strategic acquisitions as part of their inorganic growth strategy, seeking to augment sales and profit margins.

Strategic mergers and acquisitions continue to be crucial competitive strategies employed by key players, allowing them to expand their product offerings, gain access to new technologies, and increase their market share. Vendors also prioritize the development and commercialization of innovative analyzers, COVID-19 PCR rapid test kits, and consumables in order to maintain competitiveness and establish a significant presence in the IVD raw materials market.

Key companies profiled in this report include Aalto Bio Reagents, Fapon Biotech, Fujirebio, Merck KGaA, Hoffmann-La Roche, Thermo Fisher Scientific, ABclonal, BBI Solutions, Beijing Diagreat Biotechnology, Biofootprints Healthcare, BioPorto, Creative Diagnostics, CUSABIO Technology, EUPROTEIN, Eximio Biotec, GenScript ProBio, Getein Biotech, Glentham Life Sciences, HyTest , ImmunoDiagnostics, LGC, Medix Biochemica, Meridian Bioscience, More Diagnostics, MP Biomedicals, Nanjing Okay Biotechnology, Nitto Boseki, OYC Europe, Prahas Healthcare, Promega, ReAgent, Rockland Immunochemicals, Sekisui Diagnostics, SERION Immunologics, Signalway Antibody, Suzhou Yacoo Science, Trina Bioreactives, Watson International, Wuhan Huamei Biotech.

---

Key Questions Answered

---

How large is the IVD raw materials market?

The IVD raw materials market is projected to reach USD 34.25 billion by 2027.

What factors contribute to the growth of the IVD raw materials market?

The growth enablers in the IVD raw materials market include an increasing prevalence of infectious and chronic diseases, growing awareness for early diagnosis and disease prevention, and a surge in demand for IVD testing and devices.

Who are the major players in the IVD raw materials market?

The key players in the IVD raw materials market are Aalto Bio Reagents, Fapon Biotech, Fujirebio, Merck KGaA, F. Hoffmann-La Roche, and Thermo Fisher Scientific.

Which region has the largest share in the IVD raw materials market?

Europe holds the largest share in the IVD raw materials market.

What are the significant trends in the IVD raw materials market?

The significant trends in the IVD raw materials market include rising demand for point-of-care PCR diagnostics, personalized medicine, and molecular diagnostics.